The Readout Loud

@thereadoutloud · Podcast

Latest segments

• RasenQ's price tag, 2026-10-30
  Surveys the wider KRAS field the approval opened
  Surveys the wider KRAS field the RasenQ approval opened up: G12D inhibitors such as Insilico's combined with chemotherapy in pancreatic cancer, and a debate over mutation-specific versus pan-KRAS drugs. Frames the approval as the starting gun rather than the finish line.
• Moderna cancer vaccine leak, 2026-10-30
  Recaps the embargo break and the sell-off
  Recaps the embargo break and the sell-off, framing the drop as a market reaction after Moderna added about $60 billion in market value since August, not a verdict on the data. Stays inside the leak coverage already on the record.
• Moderna-Merck vaccine data, 2026-10-30
  Adds the cost and access questions
  Turns to cost and access: Keytruda's decade as standard of care, copycat versions due in a few years, and the vaccine's expected hefty price tag. Drew's sit-down with Bancel adds the pipeline map - kidney cancer data at year-end or early next year, lung cancer as the big test.
• Moderna-Merck vaccine data, 2026-10-30
  Walks through the 42% progression reduction
  Walks through the ESMO readout of the intismeran-Keytruda data: the 42% reduction in disease progression versus Keytruda alone in adjuvant melanoma, and the debate over how broadly personalized cancer vaccines will work. A retelling of the disclosed numbers, with the vaccine's name and the conference setting added.
• NIH peer review score proposal, 2026-10-08
  Interviews reporters on NIH's discretionary funding shift
  Interviews a STAT reporter and an AAMC policy lead on how the NIH actually spent its 2026 budget: the shift from peer review scores to program officer and institute director discretion, the December 2025 unified funding strategy, and the collapse in health disparities and race-related awards.